Repligen other research news
RGEN (Cambridge, Mass.) presented in vitro results showing that its blocker of creatine kinase synergizes with a variety of chemotherapeutic agents to kill human cancer cells.
At the meeting of the American Association of Cancer Research, AM285 showed greater than additive effects on small-cell lung cancer cells when combined with standard anticancer agents, including cis-platinum, cyclophosphamide, 5-FU and adriamycin. Other data presented at the meeting showed that the small molecule alone was active in various in vitro and in vivo models of cancer. In vivo, the agent was more effective intravenously than intraperitoneally (doses compared were 0.5 or 1 g/kg) and the drug did not produce additional toxicity when AM285 was given for 10 days with the full standard dose of each chemotherapeutic, the company reported. ...